Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
FOLD 
Amicus Therapeutics Inc (FOLD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: FOLD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -17.48% | Avg. Invested days 37 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.45B USD | Price to earnings Ratio - | 1Y Target Price 16.73 |
Price to earnings Ratio - | 1Y Target Price 16.73 | ||
Volume (30-day avg) 2752796 | Beta 0.69 | 52 Weeks Range 7.84 - 12.65 | Updated Date 04/2/2025 |
52 Weeks Range 7.84 - 12.65 | Updated Date 04/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -10.62% | Operating Margin (TTM) 10.67% |
Management Effectiveness
Return on Assets (TTM) 2.72% | Return on Equity (TTM) -31.68% |
Valuation
Trailing PE - | Forward PE 434.78 | Enterprise Value 2636254728 | Price to Sales(TTM) 4.65 |
Enterprise Value 2636254728 | Price to Sales(TTM) 4.65 | ||
Enterprise Value to Revenue 4.99 | Enterprise Value to EBITDA 89.7 | Shares Outstanding 307240000 | Shares Floating 250897044 |
Shares Outstanding 307240000 | Shares Floating 250897044 | ||
Percent Insiders 0.83 | Percent Institutions 100.62 |
Analyst Ratings
Rating 4.42 | Target Price 17.09 | Buy 1 | Strong Buy 8 |
Buy 1 | Strong Buy 8 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Amicus Therapeutics Inc
Company Overview
History and Background
Amicus Therapeutics was founded in 2002. It focuses on developing treatments for rare diseases, initially concentrating on chaperone therapies. Key milestones include the approval of Galafold for Fabry disease and progressing its pipeline of gene therapy candidates.
Core Business Areas
- Rare Disease Therapeutics: Amicus develops and commercializes therapies for rare genetic diseases, primarily focusing on lysosomal storage disorders.
- Gene Therapy: Amicus is developing gene therapies for various rare diseases, with a focus on Pompe disease and other metabolic disorders.
Leadership and Structure
John F. Crowley is the Chairman and Chief Executive Officer. The company has a typical pharmaceutical organizational structure with departments for research, development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Galafold (migalastat): Galafold is an oral chaperone therapy approved for certain amenable mutations in Fabry disease. Competition includes enzyme replacement therapies (ERTs) from Sanofi (ENZYME) and Takeda (TAK). Worldwide Galafold revenue was 366.5 million USD in 2023. Market share is difficult to accurately determine due to varying patient populations and treatment options.
- Pombiliti + Opfolda: A treatment for late-onset Pompe disease. Approved in the US in May 2023. Competition includes Lumizyme (alglucosidase alfa) and Nexviazyme (avalglucosidase alfa-ngpt) from Sanofi (SNY). 2023 full-year revenue for Pombiliti + Opfolda: 153.2 million USD.
Market Dynamics
Industry Overview
The rare disease therapeutics market is growing rapidly due to increased awareness, orphan drug incentives, and advancements in gene therapy. The market is competitive, with both established pharmaceutical companies and smaller biotech firms.
Positioning
Amicus Therapeutics positions itself as a leader in developing innovative therapies for rare genetic diseases, particularly through its expertise in chaperone therapies and gene therapy. Its competitive advantage lies in its focused approach and established commercial infrastructure.
Total Addressable Market (TAM)
The global rare disease therapeutics market is estimated to reach over $250 billion USD by 2030. Amicus's TAM is focused on Fabry disease and Pompe disease initially, but it plans to expand to other rare diseases. Amicus has an active approach towards this TAM.
Upturn SWOT Analysis
Strengths
- Approved therapies (Galafold, Pombiliti + Opfolda)
- Gene therapy pipeline
- Strong focus on rare diseases
- Established commercial infrastructure
- Experienced management team
Weaknesses
- Reliance on a few key products
- High R&D expenses
- Regulatory and clinical trial risks
- Competition from larger pharmaceutical companies
Opportunities
- Expanding indications for existing therapies
- Advancing gene therapy pipeline
- Acquiring or partnering with other rare disease companies
- Geographic expansion
Threats
- Competition from new therapies
- Regulatory setbacks
- Pricing pressures
- Clinical trial failures
- Intellectual property challenges
Competitors and Market Share
Key Competitors
- SNY
- TAK
- BMY
- VRTX
- RGNX
Competitive Landscape
Amicus faces competition from larger pharmaceutical companies with greater resources, as well as smaller biotech firms focused on specific rare diseases. Amicus's strength lies in its expertise in chaperone therapies and gene therapy, but it needs to continue to innovate and expand its pipeline to maintain its competitive edge.
Major Acquisitions
Callidus Biopharma
- Year: 2020
- Acquisition Price (USD millions): 400
- Strategic Rationale: Expanded Amicus's gene therapy pipeline and added expertise in lysosomal storage disorders.
Growth Trajectory and Initiatives
Historical Growth: Amicus has experienced significant revenue growth driven by the commercial success of Galafold and initial sales of Pombiliti + Opfolda.
Future Projections: Analysts project continued revenue growth driven by increasing sales of existing therapies and potential approvals of new gene therapies. Profitability is expected to improve over time.
Recent Initiatives: Recent initiatives include expanding the Galafold label, advancing the gene therapy pipeline, and seeking regulatory approvals for new therapies.
Summary
Amicus Therapeutics is a company specializing in rare diseases with approved therapies and a growing gene therapy pipeline. While revenue is increasing, the company is still operating at a loss due to high R&D costs. Success depends on expanding their product portfolio and navigating regulatory hurdles. Competition remains a significant factor that must be taken into account in order for Amicus Therapeutics Inc to be successful.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
MRNA
Moderna Inc
MRNA
Moderna Inc
RGNX
Regenxbio Inc
RGNX
Regenxbio Inc
SNY
Sanofi ADR
SNY
Sanofi ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
VRTX
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
Sources and Disclaimers
Data Sources:
- Amicus Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Company Press Releases
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amicus Therapeutics Inc
Exchange NASDAQ | Headquaters Princeton, NJ, United States | ||
IPO Launch date 2007-05-31 | CEO, President & Director Mr. Bradley L. Campbell M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 499 | Website https://amicusrx.com |
Full time employees 499 | Website https://amicusrx.com | ||
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company's commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.